KYOWA HAKKO BIO CO.,LTD.

KYOWA HAKKO BIO CO.,LTD. Climate Commitments and Emissions Overview

KYOWA HAKKO BIO CO.,LTD., a Japanese Pharmaceutical Preparation Manufacturing company, reported global Scope 1 emissions of approximately 33,000,000 kg CO2e, Scope 2 emissions of about 96,000,000 kg CO2e, and Scope 3 emissions of approximately 176,000,000 kg CO2e for the 2023 reporting year. This data is specific to Kyowa Hakko Bio Co., Ltd.

The company has set near-term absolute reduction targets. They aim for a 50% reduction in combined Scope 1 and Scope 2 emissions and a 30% reduction in Scope 3 emissions by 2030, both compared to 2019 levels. In 2019, Kyowa Hakko Bio Co., Ltd. reported Scope 1 emissions of approximately 47,000,000 kg CO2e, Scope 2 emissions of about 196,000,000 kg CO2e, and Scope 3 emissions of approximately 234,000,000 kg CO2e.

Historical emissions data shows a trend: in 2022, Scope 1 emissions were approximately 40,000,000 kg CO2e, Scope 2 emissions were about 131,000,000 kg CO2e, and Scope 3 emissions were approximately 193,000,000 kg CO2e. In 2021, these figures were approximately 41,000 kg CO2e for Scope 1, 161,000 kg CO2e for Scope 2, and 190,000 kg CO2e for Scope 3. For 2020, Scope 1 emissions were about 44,000 kg CO2e, Scope 2 emissions were approximately 175,000 kg CO2e, and Scope 3 emissions were around 189,000 kg CO2e.

KYOWA HAKKO BIO CO.,LTD. is a current subsidiary of Kirin Holdings Company, Limited, and inherits its climate initiative sources for SBTi, CDP, RE100, and RTZ from Kirin Holdings Company, Limited.